O
Optra Scan
Optra SCAN | Integrated Digital Pathology Scanning Solutions
About Optra Scan
OptraScan, founded in 2014 by Abhi Gholap, operates in the digital pathology sector, providing affordable and advanced whole slide imaging systems. The company is a subsidiary of Optra Ventures, which focuses on creating disruptive technology solutions. Gholap's background includes founding Sciformix Corporation, a scientific knowledge-based organization, and BioImagene, a digital pathology company acquired by Roche in 2010, experiences that directly inform OptraScan's mission.
The company's business model centers on an "On-Demand" subscription service, making digital pathology accessible to a wider range of clients, including hospitals, diagnostic labs, and research institutions. This approach eliminates the need for large upfront capital expenditures, a significant barrier to adopting digital pathology. Revenue is generated through subscriptions to their scanning devices and accompanying software solutions. OptraScan's solutions are designed to be compact and user-friendly, allowing for seamless integration into existing laboratory workflows.
OptraScan offers a comprehensive suite of products and services. Their core offerings are the OS-15 and OS-Ultra series of whole slide scanners, which digitize glass slides for analysis, storage, and sharing. These scanners are complemented by a suite of software, including the image viewing platform IMAGEPath, the image analysis tool OptraASSAYS, and the cloud-based LIMS, CLOUDPath. To enhance diagnostic capabilities, the company incorporates artificial intelligence and machine learning algorithms for tasks like image analysis, pattern recognition, and computer-aided region detection, aiming to improve accuracy and efficiency for pathologists.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- San Jose, United States
- Employees
- 65
- Open positions
- 3
- Dealroom signal
- 89.8/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Health, Pathology, Medical Imaging, Health Diagnostics, Health It, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Nov 2024 | $30M | $120M | Molbio Diagnostics | ↗ |
Growth signals
Latest recorded traffic for Optra Scan is 3.6K monthly website visits, up 38.5% over the last three months. Optra Scan's team grew 62.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Molbio Diagnostics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Optra Scan on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Optra Scan’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.